Background: Osteoporotic fractures still remain very infrequent and physicians rarely evaluate bone health. We wanted to assess the magnitude of this problem in the near future by determining the risk and likelihood of progression to osteoporosis.
Introduction
HIV-infected people have a high risk of osteoporosis owing to multiple factors related not only to the host, but also to the virus, chronic inflammation and ART. [1] [2] [3] [4] [5] [6] [7] [8] Evidence from large cohort studies points to a higher prevalence of low-energy fractures in HIV-infected people than in the general population 5, 7, [9] [10] [11] [12] [13] [14] However, despite the many recently published recommendations on management of bone disease in HIV-infected individuals [15] [16] [17] [18] [19] the current low frequency of fracture managed in our daily clinical practice could make physicians less likely to evaluate bone health. Consequently, osteoporosis seems to be underdiagnosed and, consequently, undertreated in HIV-infected persons, thus leaving this population vulnerable to early fractures and disability. 20 However, in ageing persons, the long-term nature of HIV infection, persistent systemic inflammatory status and prolonged exposure to antiretroviral drugs make the number of bone fractures among this population likely to increase. This is especially true in individuals aged 50 years or older. 10, 13 Therefore, clinicians should be aware of problems affecting the bone and proactively manage bone health.
In this study, we estimated the magnitude of an emerging problem among chronically HIV-infected persons by studying the progression to osteopenia/osteoporosis in a large cohort of patients assessed using DXA scans. 
Methods

Study design, population and objective
We performed a retrospective longitudinal observational study of all DXA scans from HIV-infected patients who attended our HIV Unit and who had had at least two DXA scans between January 1999 and December 2016.
The analysis included 3726 DXA scans from 875 patients. The scans were requested as part of patient follow-up in clinical practice or in the context of clinical trials. In recent years, DXA scans have been requested according to current recommendations for HIV-infected persons as follows: mainly before starting ART, men aged .50 years, menopausal women, persons with a history of bone fractures, or patients using drugs or with diseases associated with a decrease in bone mineral density. 16, 18 The main objective of the study was to evaluate the risk of progression of bone loss. Patients were classified into three groups according to their bone mineral density: normal bone mineral density, osteopenia and osteoporosis. We estimated the following: (i) the percentage of patients in each group at the first and last DXA scan; (ii) the number of transitions from one group to another (normal bone mineral density to osteopenia, osteopenia to normal bone mineral density, osteopenia to osteoporosis, or osteoporosis to osteopenia); (iii) the risk of progression of bone loss or bone gain; (iv) the probability of progression over time; and (v) the risk of low bone mineral density associated with the antiretroviral drugs used during the year before each DXA scan [tenofovir disoproxil fumarate, PIs, combination of both (tenofovir disoproxil fumarate and PIs) and the use of lopinavir, atazanavir or darunavir, specifically].
The T score for the lumbar spine (L1-L4) and hip (femoral neck, trochanter and total femur) measured by DXA (Lunar Prodigy, GE Healthcare, Belgium) was collected and the minimum of the four T scores was considered for patient classification. Osteopenia and osteoporosis were defined following the criteria of the WHO, as follows: normal bone mineral density, minimum T score . #1.0 SD; osteopenia, minimum T score #1.0 SD to #2.5 SD; and osteoporosis, minimum T score , #2.5 SD. 21 
Statistical analysis
Categorical variables of interest were described using absolute and relative frequencies; numerical variables were described using the median and IQR.
The bone mineral density history was studied following a multistate model as shown in Figure 1 . Multistate models are useful to study the evolution of a disease that can be classified into different stages. They are characterized by its states, the possible transitions among them and the corresponding instantaneous transition rates or intensities, which can be modelled as functions of covariates of interest by means of separate proportional hazard models. The model shown in Figure 1 The choice of this cut-off value was based on 45 years being the average midpoint of the age intervals from the first to the last DXA scan.
Based on the estimates of the transition intensities, transition probabilities can be estimated as a function of age by means of mathematical formulae involving power series. 22 The estimation of the transition probabilities was made first by using separate models without covariates for both women and men. Next, the use of antiretroviral drugs during the year prior to the DXA scan was included as a covariate in the model, in four different ways: PI versus no PI; tenofovir versus no tenofovir; combined use of PI and tenofovir; and specific PI (atazanavir, darunavir, lopinavir or other). The possible effects of these drugs were studied by transition-specific hazard regression models, which provide the HR as the effect size measure of interest. 
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All statistical analyses were performed using R (R Foundation for Statistical Computing, Vienna, Austria), version 3.3.2; in particular, the msm package, which enables a multistate model to be fitted to panel data, that is, with observations of a continuous-time process at arbitrary times. 23 
Results
The analysis included 3726 DXA scans from 875 patients who had had at least 2 DXA scans. During the 18 years of follow-up, the median number of scans per patient was 3 (range 2-18), the median (IQR) time from the first to the last DXA scan was 5 (2.2-9.6) years and the median (IQR) time between consecutive DXA scans was 1.1 (0.6-2.2) years. Among the 875 patients, 294 (33.6%) had two DXA scans, 188 (21.5%) had three DXA scans, 118 (13.5%) had four DXA scans and 275 (31.4%) had five or more DXA scans.
The median (IQR) age of the cohort at the first DXA scan was 41.7 (36.1-47.8) years and 75.3% were men. The median CD4 nadir (IQR) was 234 (115-336) cells/mm 3 and 112 (12.8%) patients had an AIDS diagnosis prior to the first DXA scan. Epidemiological and clinical data at the time of the first DXA scan are summarized in Table 1 .
Prevalence and transitions
The overall percentages of patients in the three groups at the first DXA scan were as follows: 31.1% for normal bone mineral density, 52.2% for osteopenia and 16.7% for osteoporosis. At the last DXA scan these values were 28.1% for normal bone mineral density, 54.5% for osteopenia and 17.4% for osteoporosis. Figure 1 (a) shows the joint distribution of the states at the first and the last DXA scan.
The total numbers of DXA scans among the 659 men and 216 women were 2828 and 898, respectively. Hence, there were 2169 (2828 # 659) transitions in subsequent DXA scans in men and 682 (898 # 216) transitions in women; the corresponding distributions are shown in Figure 1 (b and c). A deterioration in bone mineral density from one DXA scan to the next was observed in 174 (8%) transitions among men (94 from normal bone mineral density to osteopenia and 80 from osteopenia to osteoporosis) and in 75 (11%) transitions among women (46 from normal bone mineral density to osteopenia and 29 from osteopenia to osteoporosis). An improvement was observed in 178 (8.2%) transitions and 37 (5.4%) transitions among men and women, respectively.
Risk of progression
The risk of progression of bone loss or bone gain was studied as a function of age (.45 versus 45 years). The HRs associated with age for HIV-infected patients were as follows: (i) transition from normal bone mineral density to osteopenia, 0.71 (95% CI 0.45-1.11) for men and 1.06 (95% CI 0.55-2.05) for women; (ii) transition from osteopenia to osteoporosis, 0.83 (95% CI 0.51-1.35) for men and 0.99 (95% CI 0.38-2.56) for women; (iii) transition from osteopenia to normal bone mineral density, 0.41 (95% CI 0.26-0.65) for men and 0.42 (95% CI 0.18-0.99) for women; and (iv) transition from osteoporosis to osteopenia, 0.67 (95% CI 0.42-1.05) for men and 0.12 (95% CI 0.04-0.36) for women. Figure 2 shows the estimated HRs associated with age for both genders.
Probability of progression
Figure 3(a) shows the estimated probabilities of progression from normal bone mineral density to osteopenia/osteoporosis over 10 years among HIV-infected men and women aged 30, 40 and 50 years. Given a normal bone mineral density at baseline, the probability that a 30-year-old HIV-infected man will progress to either osteopenia or osteoporosis at age 40 is 60.6% (95% CI 53.9%-69.7%) and 51.1% (95% CI 39%-64.5%) for a 30-year-old woman. The corresponding probabilities of progression for men and women aged 40 to 50 years, respectively, are 62.6% (95% CI 55.8%-70.5%) and 59.5% (95% CI 50.1%-70.1%), and for those aged 50 to 60 years, 59.7% (95% CI 49.2%-71.1%) and 62.4% (95% CI 47.2%-77.3%).
With respect to the transition from osteopenia to osteoporosis, the estimated transition probabilities over 10 years are shown in Figure 3(b) . In HIV-infected men aged 30, 40 and 50 years, the probabilities were 14.9% (95% CI 10.5%-20.4%), 17.2% (95% CI 14%-21.3%) and 19% (95% CI 14.3%-24.3%), respectively. A different probability pattern was obtained for women, with values 
Risk of low bone mineral density according to ART
Information on ART regimens 1 year before the DXA scans was available for 862/875 (98.5%) patients, i.e. 3516/3726 (94.4%) DXA scans ( Table 1 ). The estimated HRs associated with treatment combinations containing PI/tenofovir for both deterioration transitions are shown in Figure 4 (a) (men) and Figure 4 (b) (women), respectively. In only the cases of HIV-infected women, increased risks of osteoporosis were observed both for use of PIs compared with no PI ! no tenofovir (HR 5.9; 95% CI 1.2-27.6) and for combined use of PIs ! tenofovir disoproxil fumarate compared with no PI ! no tenofovir (HR 6.9; 95% CI 1.4-34.4). The corresponding values among HIV-infected men were 1.8 (95% CI 0.9-3.4) and 1.2 (95% CI 0.6-2.6), respectively.
Darunavir was associated with a higher risk of osteoporosis among men (HR 3.9; 95% CI 2-7.5) and women (HR 4.5; 95% CI 1.4-14.7), as well as with a higher risk of osteopenia among women (HR 2.8; 95% CI 1.1-7.1) (Figure 5a and b) . In addition, atazanavir increased the risk of osteoporosis among women (HR 4.2; 95% CI 1.3-14), although this varied little among men (HR 1.2; 95% CI 0.4-3.2). The always-larger CIs among HIV-infected women result from the smaller sample size and the small number of transitions.
A sensitivity analysis considering cut-off values other than 45 years (.40 versus 40 years and .50 versus 50 years) was carried out to ensure that the conclusions on the effects of ART did not depend on that choice. The models using different cut-offs The previous analysis did not vary when we included other variables in the multistate models such as route of HIV transmission, AIDS diagnosis or nadir CD4 T cell counts (data not shown).
Discussion
The prevalence of osteopenia and osteoporosis was high in our cohort. The risk and the probability of progression from osteopenia to osteoporosis over 10 years were higher among women, especially those aged over 40 years; for men, the risk increased progressively, although the increment was more attenuated. Therapy with darunavir and atazanavir was associated with an increased risk of progression to bone loss.
Osteoporosis is a major public health problem owing to the impact of osteoporotic bone fracture, for which the health consequences include not only chronic pain, respiratory compromise, reduced mobility, disability and mortality, but also increased social cost because of lost workdays, increased health and nursing care, and long-term rehabilitation. Consequently, assessment of the risk of fracture should be a high priority among health measures. Since the mid-1990s, the WHO operational definition of osteoporosis has been based on measurement of bone mineral density using DXA in order to identify persons at higher risk of bone fracture. It is well known that decreases in vertebral and hip bone mineral density predict vertebral fractures [relative risk (RR) 2.3; 95% CI 1.9-2.8] and hip fractures (RR 2.6; 95% CI 2.0-3.5), respectively. 24 The rate of osteoporosis appears to be greater in HIVinfected individuals than in the general population and is progressively increasing. 8 In our cohort of almost 900 persons, of whom 25% were women, only a third of the population had normal bone mineral density; half had osteopenia and 17% Progression to osteoporosis in HIV infection JAC osteoporosis. These rates are similar to those observed in other cohorts 5, 25 and support the significance of this condition in HIVinfected persons.
Nevertheless, osteoporotic fractures still remain very infrequent in daily clinical practice and physicians rarely evaluate the risk of fractures. We wanted to assess the magnitude of this problem in the near future by determining the risk and likelihood of progression to osteoporosis in 10 years in a large cohort of chronically HIVinfected persons assessed using the DXA scan, with a median of three scans per patient (more than 60% had three or more scans) and a median of 5 years from the first to the last DXA scan. Owing to the lack of available software, these rather complex models were not frequently applied in the past. Nowadays, however, thanks to software packages such as the one used by us (R msm package), multistate models are becoming more and more popular since they permit the joint study of the transitions among different stages of disease.
First, in order to obtain an overview of progression of bone loss in the DXA scans, we analysed transitions from one DXA scan to the next. Deterioration of bone mineral density-defined as a change in status from normal bone mineral density to osteopenia or from osteopenia to osteoporosis between two consecutive DXA scans-was observed in around 10% of transitions; this rate was considerably high, considering that the median time between consecutive DXA scans was only 1 year. Improvement was observed in 5%-8% of transitions and the difference was similar in men and women.
When the risk of progression was calculated according to age (.45 versus 45 years, .40 versus 40 years and .50 versus 50 years) and gender, the risk of bone loss changed little with age. The low number of patients aged 60 or over included in the study could make it difficult to detect differences in deterioration between age groups. On the other hand, as expected, the risk of recovery (bone gain) was more likely for patients younger than 45 years. This finding supports the assessment of bone health at early ages and suggests that intensive interventions should be implemented, if necessary, at early stages of bone loss to achieve better recovery. Bone mineral density could improve mainly as a consequence of changes in lifestyle and the use of vitamin D supplements, and, in a low proportion of subjects, by the use of biphosphonates. Unfortunately, this information is not available at each DXA scan.
However, when we evaluated the probability of progression over time, it is noteworthy that the probability of progression from normal bone mineral density to osteopenia/osteoporosis over 10 years was very high, around 50%-60%, and similar between men and women and for persons aged 30, 40 or 50 years. In other words, at the age of 30 years, the probability of progression to osteopenia was as high as 60.6% for men and 51.1% for women at 10 years. In contrast, when we evaluated the probability of progression from osteopenia to osteoporosis, larger differences between age and gender were obtained; the estimated risks of progression were 14.9%, 17.2% and 19% for men at age 30, 40 and 50 years, respectively, and 6.9%, 21.1% and 30.1%, respectively, for women. These data indicate that with respect to a 30-year-old woman, the risk of progressing to osteoporosis is 3-fold higher in a 40-year-old woman, and almost 5-fold higher in a 50-year-old woman, whereas in a man, the risk of progression is much lower.
As for ART, in addition to evidence for tenofovir, there is evidence of a potential negative effect of PIs on bone mineral density. 7, 8, 25, 26 In Japanese HIV-infected patients, treatment with a PI correlated significantly with bone loss, whereas discontinuation of the PI enabled bone recovery, especially in the lumbar spine. 25 Our results confirm the impact of PIs on bone loss, which was significant among women taking PIs and PIs ! tenofovir. In men, a trend towards the risk of osteoporosis was seen with the use of PIs. However, it is unknown whether this is a class effect of all PIs or whether it is an adverse effect of a specific PI. To our knowledge, there are no firm data about the specific role of each individual PI in bone loss. Our large sample size made it possible to evaluate the individual impact of the most commonly used PIs (atazanavir, lopinavir and darunavir). Having a closer look at the specific PIs, darunavir was associated with risk of bone loss among men and women, whereas atazanavir was only associated with this risk in women. These results, together with data from studies in which the PI is replaced or interrupted, 25, 27 support the recommendation to avoid or change PIs, if possible, in the case of osteoporosis. 16 However, this finding should be interpreted with caution because only the antiretroviral combination received during the year before the DXA scan was analysed. The retrospective nature of the study prevents us from evaluating the cumulative and continuous effect of each antiretroviral agent. In addition, the effect of other secondary risk factors on bone loss, such as menopause, the use of treatment for osteoporosis, BMI or hepatitis coinfections was not assessed since this information was not available at each DXA scan.
Concerning methodological aspects and possible limitations, we are aware of the fact that studying the bone mineral density by means of multistate models implies a loss of information even though the definition of the states used follows the definition of the WHO. Nonetheless, we decided to use and fit multistate models to the data for two reasons. First, clinical practice is based on the categorization of bone mineral density into normal bone mineral density, osteopenia and osteoporosis. It is hence of medical interest to know, for example, what the probability is of a patient with normal bone mineral density of suffering from osteopenia within a certain period. Second, the course of bone mineral density is hard to capture with a standard regression model given the fact that bone mineral density might both improve and deteriorate over time. On the other hand, the large sample size of more than 3000 DXA scans of 875 HIV-infected patients during a period of 17 years is one of the strengths of this study. It would require an enormous logistic and financial effort to obtain such a large sample with a prospective study.
In conclusion, given the increased prevalence of osteoporosis and risk of bone fractures in HIV-infected individuals, osteoporosis and other factors leading to fracture, such as sarcopenia, should be regularly assessed in clinical practice. DXA scans or fracture prediction algorithms such as the FRAX V R equation 28 help to identify individuals at risk. Our results highlight the need for monitoring of bone mineral density owing to the high probability of progression to osteopenia, even at early ages, in both genders, and to osteoporosis, especially in women aged 40 years. In addition, changes in antiretroviral drugs other than tenofovir (e.g. PIs), changes in lifestyle and nonpharmacological and pharmacological interventions should be Negredo et al.
recommended among patients at high risk to reduce the risk of recurrence of fracture in the coming decade.
